The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience

Creative Commons License

ESER A., Timuragaoglu A.

BEZMIALEM SCIENCE, vol.9, no.1, pp.98-105, 2021 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.14235/bas.galenos.2020.5582
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.98-105
  • Bezmialem Vakıf University Affiliated: Yes


Objective: Persistent thrombocytopenia is a common complication of allogeneic stem cell transplantation (ASCT). Treatment of platelet engraftment failure after ASCT remains controversial. Drugs, such as eltrombopag, are used for this purpose. Eltrombopag is an Food and Drug Administration -approved oral thrombopoietin receptor agonist. We aim to present the results of 12 patients treated with eltrombopag in our center for severe thrombocytopenia after ASCT.